Company Registration No. 05122945 (England and Wales)
REPRODUCTIVE IMMUNOLOGY CENTRE LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023
REPRODUCTIVE IMMUNOLOGY CENTRE LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
REPRODUCTIVE IMMUNOLOGY CENTRE LTD
BALANCE SHEET
AS AT
31 MAY 2023
31 May 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
3
555,105
555,527
Current assets
Debtors
84,681
89,699
Cash at bank and in hand
213,068
174,956
297,749
264,655
Creditors: amounts falling due within one year
(67,381)
(71,898)
Net current assets
230,368
192,757
Total assets less current liabilities
785,473
748,284
Creditors: amounts falling due after more than one year
4
-
0
(98,219)
Net assets
785,473
650,065
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
785,373
649,965
Total equity
785,473
650,065

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 May 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 13 March 2024 and are signed on its behalf by:
B Ford
Director
Company registration number 05122945 (England and Wales)
REPRODUCTIVE IMMUNOLOGY CENTRE LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023
- 2 -
1
Accounting policies
Company information

Reproductive Immunology Centre Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Guardsworth House, 85 Gloucester Road, Croydon, CR0 2DN.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings Freehold
No depreciation
Plant and machinery
50% straight line basis
Fixtures, fittings & equipment
50% straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

REPRODUCTIVE IMMUNOLOGY CENTRE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2023
1
Accounting policies
(Continued)
- 3 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

REPRODUCTIVE IMMUNOLOGY CENTRE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2023
1
Accounting policies
(Continued)
- 4 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax
The accounting policy in respect of deferred tax fully reflects the requirements of FRS19 - Deferred tax. Deferred tax is provided in full in respect of taxation deferred by timing differences between the treatment of certain items for taxation and accounting purposes.
1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

REPRODUCTIVE IMMUNOLOGY CENTRE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2023
- 5 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
4
4
3
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 June 2022
552,385
194,849
747,234
Additions
-
0
5,441
5,441
At 31 May 2023
552,385
200,290
752,675
Depreciation and impairment
At 1 June 2022
-
0
191,708
191,708
Depreciation charged in the year
-
0
5,862
5,862
At 31 May 2023
-
0
197,570
197,570
Carrying amount
At 31 May 2023
552,385
2,720
555,105
At 31 May 2022
552,385
3,142
555,527
4
Creditors: amounts falling due after more than one year
2023
2022
£
£
Bank loans and overdrafts
-
0
98,219
2023-05-312022-06-01false13 March 2024CCH SoftwareCCH Accounts Production 2024.100No description of principal activityA BansalS BhaskaranB FordB Fordfalsefalse051229452022-06-012023-05-31051229452023-05-31051229452022-05-3105122945core:LandBuildings2023-05-3105122945core:OtherPropertyPlantEquipment2023-05-3105122945core:LandBuildings2022-05-3105122945core:OtherPropertyPlantEquipment2022-05-3105122945core:CurrentFinancialInstrumentscore:WithinOneYear2023-05-3105122945core:CurrentFinancialInstrumentscore:WithinOneYear2022-05-3105122945core:Non-currentFinancialInstrumentscore:AfterOneYear2023-05-3105122945core:Non-currentFinancialInstrumentscore:AfterOneYear2022-05-3105122945core:ShareCapital2023-05-3105122945core:ShareCapital2022-05-3105122945core:RetainedEarningsAccumulatedLosses2023-05-3105122945core:RetainedEarningsAccumulatedLosses2022-05-3105122945bus:Director32022-06-012023-05-3105122945core:LandBuildingscore:OwnedOrFreeholdAssets2022-06-012023-05-3105122945core:PlantMachinery2022-06-012023-05-3105122945core:FurnitureFittings2022-06-012023-05-31051229452021-06-012022-05-3105122945core:LandBuildings2022-05-3105122945core:OtherPropertyPlantEquipment2022-05-31051229452022-05-3105122945core:LandBuildings2022-06-012023-05-3105122945core:OtherPropertyPlantEquipment2022-06-012023-05-3105122945core:Non-currentFinancialInstruments2023-05-3105122945core:Non-currentFinancialInstruments2022-05-3105122945bus:PrivateLimitedCompanyLtd2022-06-012023-05-3105122945bus:SmallCompaniesRegimeForAccounts2022-06-012023-05-3105122945bus:FRS1022022-06-012023-05-3105122945bus:AuditExemptWithAccountantsReport2022-06-012023-05-3105122945bus:Director12022-06-012023-05-3105122945bus:Director22022-06-012023-05-3105122945bus:CompanySecretary12022-06-012023-05-3105122945bus:FullAccounts2022-06-012023-05-31xbrli:purexbrli:sharesiso4217:GBP